Quest Diagnostics is a leading global provider of diagnostic information services, specializing in laboratory testing and related services. The company offers a comprehensive range of medical testing, including routine blood work, genetic testing, and specialized diagnostic imaging, aimed at helping healthcare providers make informed decisions about patient care. With a vast network of laboratories and patient service centers, Quest Diagnostics plays a critical role in the healthcare ecosystem by delivering accurate and timely results, contributing to enhanced patient outcomes and supporting public health initiatives. Through their innovative technologies and dedication to quality, the company strives to advance the practice of medicine and improve overall health management. Read More
Join us as we analyze Quest Diagnostics and uncover whether this lab giant is a smart investment choice for the future. With insights from industry experts, you won't want to miss this evaluation!
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting with Quest (NYSE:DGX).
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.2% year on year to $2.76 billion. The company’s full-year revenue guidance of $10.86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.64 per share was 2.5% above analysts’ consensus estimates.
Shares of healthcare diagnostics company Quest Diagnostics (NYSE:DGX)
jumped 6.4% in the morning session after the company reported strong second-quarter financial results that beat Wall Street expectations and raised its full-year guidance.
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) announced better-than-expected revenue in Q2 CY2025, with sales up 15.2% year on year to $2.76 billion. The company’s full-year revenue guidance of $10.86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.62 per share was 1.9% above analysts’ consensus estimates.
